Gene or Genome – Page 17

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

9 months ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.

AstraZeneca’s New Calquence Combinations Show Promise in CLL Treatment: Potential to Shift Clinical Practice

9 months ago talkbio0Tagged AstraZeneca, BTK gene, Calquence, Chronic Lymphocytic Leukemia, Clinical Practice, CLL, Fixed-Duration, Inhibitor, obinutuzumab, venetoclax

AstraZeneca, Calquence, CLL, Chronic Lymphocytic Leukaemia, BTK Inhibitor, Venetoclax, Obinutuzumab, Clinical Practice, Fixed-Duration Treatment

BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease

9 months ago talkbio0Tagged Alfa, BioMarin, Brineura, cerliponase, Child, Deterioration, expansion, Injection of therapeutic agent, Intraventricular, Labels (device), motor ability, Neurodegenerative, Symptoms aspect, TPP1 gene, United States Food and Drug Administration

BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms

RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials

9 months ago talkbio0Tagged Agonist, Asthma, CCR4, CCR4 gene, Clinical Trials, Dermatitis, Atopic, Neoplasms, RAPT, Study on Hold, United States Food and Drug Administration, zelnecirnon

RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist

SciRhom Secures €63 Million in Series A Funding for Autoimmune Therapies

10 months ago talkbio0Tagged Autoimmune Diseases, Funding, RHBDF2 gene, SciRhom, Series, therapeutic strategy

SciRhom, autoimmune diseases, iRhom2, therapeutic strategy, Series A funding, biotech, pharmaceuticals

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

10 months ago talkbio0Tagged AMT-130, Clinical Trials, Composite, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, NEFL gene, Neurodegenerative Disorders, NfL, Phase, RMAT, Unified - Type of Agreement, UniQure, United States Food and Drug Administration

UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).